Best of ASCO - 2014 Annual Meeting

 

Welcome

Other

Melanoma/Skin Cancers

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Chronic pain and accumulation of growth factors in perifocal tissues of melanoma and impact on malignancy and early metastasis.

I. M. Kotieva

e21621

Comprehensive genomic profiling of acral and mucosal melanomas to support clinical decision making.

Anthony Classon

e21629

Differential multiparameter ultrasound diagnostics of melanocytic skin lesions using shear wave elastography.

Natalia A. Maksimova

e21627

Druggable molecular targets in skin adnexal malignancies.

Stefano Cavalieri

e21619

Effect of estrogens on growth factors in melanoma and nevi.

Valeria A. Bandovkina

e21628

EGFR to regulate angiogenesis in intact and tumor skin tissues in В16/F10 melanoma with chronic pain.

I. M. Kotieva

e21632

Hedgehog pathway inhibition by topical patidegib to reduce BCC burden in patients with basal cell nevus (Gorlin) syndrome.

Ervin H Epstein

e21626

Incidence and risk factors of retinopathy in patients with melanoma treated with high dose of interferon α-2b(HDI).

Di Wu

e21635

Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358.

Suzanne Louise Topalian

9505

Predicting overall survival in patients (pts) with treatment-naive metastatic Merkel cell carcinoma (mMCC) treated with avelumab.

Ash Bullement

e21620

Prognosis of melanoma progression based on its cytokine microenvironment.

Elena Yurievna Zlatnik

e21625

Projecting long term survival for avelumab in refractory Merkel cell carcinoma.

Hemant Phatak

e21623

Reaction of hypothalamic-pituitary-adrenal axis and its skin analogue to B16/F10 melanoma growth shows gender differences.

Valeria A. Bandovkina

e21634

Risk factors, clinical outcomes, and natural history of uveal melanoma: A single institution analysis.

Glenda Maria Delgado Ramos

e21631

Stage at presentation to determine associations between histologic parameters of primary tumor and disease specific survival (DSS) in anorectal melanoma (AM).

Priyadharsini Nagarajan

e21622

Treatment decision-making priorities and satisfaction among melanoma survivors.

Joanne S. Buzaglo

e21618

Treatment of BRAF-mutated metastatic melanoma patients with targeted therapy combinations or immunotherapy in real world setting.

Janja Ocvirk

e21630

Treatment patterns of malignant melanoma in the United States in 2011-2016: A retrospective cohort study.

Leon Raskin

e21633